Nordic Capital Completes €9.6bn Nycomed Deal
Nordic Capital Funds V and VI just completed the sale of Nycomed A/S to listed Japanese Takeda Pharmaceutical in a €9.6bn transaction. The deal excludes the US based dermatology and topical generics unit Fougera, which is being retained by the Nordic Capital-lead owner group.
30 September 2011•3 mins read
